Qualitätsbericht 2021 52 | 72 WEITERE LAUFENDE STUDIENAKTIVITÄTEN Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor Multiparametric Magnetic Resonance Imaging (MRI) to improve bladder cancer staging and treatment decision-making Onkologie Prof. Dr. med. Martin Spahn Universität Zürich Importance of exercise training therapy timing with regard to cardiotoxicity and patient preference in early breast cancer patients undergoing adjuvant chemo-therapy (CAPRICE) Onkologie, Hämatologie Dr. med. Christa Baumann Insel Gruppe Co-creating and testing the effectiveness of an integrated peer-to-peer self-management program for breast cancer survivors: A stepped wedge cluster randomized study (COSS-Study) Onkologie, Hämatologie Dr. med. Christa Baumann Krebsliga Schweiz, Schweizer Verein für Pflegewissenschaften Selbstwirksamkeits-Coaching, Mammakarzinom im Frühstadium – Pilotstudie Selbstwirksamkeitserwartung (SECOM-PSWE) Onkologie, Hämatologie Dr. med. Christa Baumann ZeTuP, iOMEDICO Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Campus Stiftung Lindenhof Bern (SLB) Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 in patients with bone metastases from castration resistant prostate cancer or from breast cancer (SAKK 96/12 REDUSE) Onkologie, Hämatologie Prof. Dr. med. Markus Borner Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Campus Stiftung Lindenhof Bern (SLB) Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: the ERYT/CoordiFit randomized controlled trial Onkologie, Hämatologie Prof. Dr. med. Markus Borner Universität Bern, Insel Gruppe Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-related Macular Degeneration Combined Protocol & Feasibility: Study 20968 Ph III – Aflibercept High Dose VAY 865321 – in patients with Age-related Macular Degeneration (20968 PULSAR Study/PXL 245919) Ophthalmologie Prof. Dr. med. Justus G. Garweg BAYER AG Validation of Biomarker Assays for Ophthalmo- logical Diseases (2021-02499) Ophthalmologie Prof. Dr. med. Justus G. Garweg BAYER AG Impact of ILM peeling for primary rhegmatogenous retinal detachment – the I-Peel Study Ophthalmologie Prof. Dr. med. Justus G. Garweg Campus Stiftung Lindenhof Bern (SLB) Study comPARing eaRly extension Of Aflibercept and Brolucizumab in Wet AMD (SPARROW) Ophthalmologie Prof. Dr. med. Justus G. Garweg Campus Stiftung Lindenhof Bern (SLB); medignition AG und Oculocare medical AG Patienten- sicherheit Medizincontrolling Lehre und Forschung Behandlungs- qualität Messungen im Überblick Patienten- zufriedenheit Qualitätsstrategie
RkJQdWJsaXNoZXIy MzQxOTE=